TY - JOUR
T1 - Background variables for the patients with invasive bladder cancer suitable for bladder-preserving therapy
AU - Miyanaga, Naoto
AU - Akaza, Hideyuki
AU - Hinotsu, Shiro
AU - Joraku, Akira
AU - Oikawa, Takehiro
AU - Sekido, Noritoshi
AU - Kawai, Koji
AU - Shimazui, Toru
PY - 2007/11
Y1 - 2007/11
N2 - Objective: The present study was undertaken to identify the patients suitable for bladder preservation by analysis of our data. Methods: The subjects of this study were all 72 patients with T2-3N0M0 bladder cancer who underwent bladder-preserving therapy in our institute. The therapy involved intra-arterial chemotherapy with MTX and CDDP and concomitant radiotherapy. Results: Of the evaluable 70 cases, complete response (CR) was confirmed in 57 cases (81.4%). Among 56 bladder preserved cases, 47 (83.9%) preserved their functioning bladder, and 9 underwent salvage radical cystectomy at the following period. The median follow-up was 45.3 months. The 5-year cause-specific survival rate was 81% and the 5-year overall survival rate was 66%. On the basis of the results of univariate analysis, variables contributing to CR were selected. In T2, tumor size of ≤3 cm was scored 0 and >3 cm was scored 1, whereas single tumor was scored 0 and multiple were scored 1. In T3, tumor size of ≤3 cm was scored 0 and >3 cm was scored 1, whereas G2 was scored 0 and G3 scored 1. The CR rates were 93.8, 92.6, and 62.9% for total scores of 0, 1, and 2, respectively (P = 0.003; score 0 or 1 versus 2). The overall survival rate was significantly higher in the former group (P = 0.003). Conclusion: Bladder-preserving therapy can be acceptable for cases of single T2N0M0 tumor with a size of ≤3 cm and for T3N0M0 cases with a tumor size of ≤3 cm.
AB - Objective: The present study was undertaken to identify the patients suitable for bladder preservation by analysis of our data. Methods: The subjects of this study were all 72 patients with T2-3N0M0 bladder cancer who underwent bladder-preserving therapy in our institute. The therapy involved intra-arterial chemotherapy with MTX and CDDP and concomitant radiotherapy. Results: Of the evaluable 70 cases, complete response (CR) was confirmed in 57 cases (81.4%). Among 56 bladder preserved cases, 47 (83.9%) preserved their functioning bladder, and 9 underwent salvage radical cystectomy at the following period. The median follow-up was 45.3 months. The 5-year cause-specific survival rate was 81% and the 5-year overall survival rate was 66%. On the basis of the results of univariate analysis, variables contributing to CR were selected. In T2, tumor size of ≤3 cm was scored 0 and >3 cm was scored 1, whereas single tumor was scored 0 and multiple were scored 1. In T3, tumor size of ≤3 cm was scored 0 and >3 cm was scored 1, whereas G2 was scored 0 and G3 scored 1. The CR rates were 93.8, 92.6, and 62.9% for total scores of 0, 1, and 2, respectively (P = 0.003; score 0 or 1 versus 2). The overall survival rate was significantly higher in the former group (P = 0.003). Conclusion: Bladder-preserving therapy can be acceptable for cases of single T2N0M0 tumor with a size of ≤3 cm and for T3N0M0 cases with a tumor size of ≤3 cm.
KW - Bladder preservation
KW - Chemotherapy
KW - Invasive bladder cancer
KW - Radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=37149007272&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=37149007272&partnerID=8YFLogxK
U2 - 10.1093/jjco/hym129
DO - 10.1093/jjco/hym129
M3 - Article
C2 - 17965422
AN - SCOPUS:37149007272
VL - 37
SP - 852
EP - 857
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
SN - 0368-2811
IS - 11
ER -
